ARTICLE | Clinical News
THVD-102: Phase II data
October 24, 2016 7:00 AM UTC
Top-line data from a double-blind, crossover Phase II trial in 24 patients with primary focal hyperhidrosis showed that twice-daily 7.5/7.5 mg oral THVD-102 oxybutynin/pilocarpine for 21 days signific...